Friday, 21 Feb 2020

You are here

The Risk of Listeriosis in RA

In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor. As investigators reviewed and refined the protocol, discussions on drug safety focused on infusion reactions and the potential for infections. However, one of our highlighted concerns was whether we should council study subjects to avoid unpasteurized or soft cheeses, including brie, as these were rich in Listeria. This Listeria concern was raised by preclinical and other data suggesting TNF was necessary to contain infections like Listeria. While the mechanisms were correct, we should have also focused on the greater worldwide pathogen - tuberculosis.

Twenty years later, Listeria is still a concern. Listeriosis is a rare infection that affects about 1600 Americans annually. In the last few years, Listeria outbreaks have been linked to contaminated cantaloupes, lettuce and now, Blue Bell ice cream. Not everyone exposed will be infected. Those at risk include the elderly, immunosuppressed, HIV+, RA, pregnant women and newborn infants. 

In 2013, Bodro et al analyzed the FDA Medwatch database and found 266 cases of Listeria monocytogenes associated with biologic use, reported between 2004 – 2011. Most of these patients' manifestations included fever, fatigue, myalgias, gastrointestinal symptoms, meningitis and other CNS manifestations. The median time to onset was 184 days and the mortality rates ranged from 11.1% (with adalimumab) to 27.3% (with rituximab). While many patients were on MTX (32%) and prednisone (56%), the drugs most commonly associated with Listeria were infliximab (77%), etanercept (12%), adalimumab (10%) and rituximab (4%), and most were treated for rheumatologic disorders (48%) or inflammatory colitis (38%). 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.